Board-certified in gastroenterology and internal medicine, Jill Smith, MD, specializes in liver disease--especially Hepatitis B & C plus inflammatory bowel disease including Crohn's disease and ulcerative colitis. Dr. Smith is known for her deep "bench to bedside" expertise, translating more than 25 years of research into innovative patient care. She often sees patients for whom previous treatments have failed and patients seeking alternative approaches to care including diet and low dose Naltrexone for inflammatory bowel disease.
In addition to patient care for adults and children, Dr. Smith has worked extensively with the FDA to develop new drugs, develop target-specific therapy and repurpose older, still effective drugs to keep medical costs down. Prior to MedStar Georgetown, she served as Director of Clinical and Translational Research at the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health and is the past President of the American Pancreatic Association.
Widely published in major clinical journals and a frequent lecturer, Dr. Smith also holds a number of patents. As professor of Medicine at Georgetown University and Professor Emeritus at Pennsylvania State University College of Medicine, she is actively involved in training and mentoring other doctors. Dr. Smith is also the recipient of numerous awards for patient care, research and teaching.
Smith JP,Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn's Disease: A Randomized Placebo-Controlled Trial. Dig Dis & Sci. 2011 Jul;56(7)2088-97.
Smith JP, Field D, Bingaman S, Evans R, Mauger D. Safety and tolerability of low dose naltrexone therapy in children with moderate to severe Crohn's Disease: a Pilot study. J Clin Gastroenterol 2013; 47:339–345. PMID:23188075.
Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, and Cantorna MT. Therapeutic effect of vitamin D supplementation in a pilot study of Crohn's patients. Clinical and Translational Gastroenterology4, e33; doi:10.1038/ctg.2013.1; published online 18 April 2013. PMID 23594800.
Smith JP, Whitcomb DC, Matters GL, Brand RE, Liao J, Huang YJ, and Frazier ML. Distribution of the CCK-B receptor genotype between pancreatic cancer patients and controls and its impact on survival. Pancreas, 44: 236-242. PMID: 25469546.
Smith JP, Fonkoua LK, and Moody TW. The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. J. Biol. Sci 2016; 12(3): 283-291.